A majority of countries report having policies to also optimise the clinical use of plasma derivatives, with a small number of countries having national prioritisation strategies to ensure supply to those patient groups who are highly dependent on treatment with these products.
Enamiku riikide teatel on neil olemas ka plasmaderivaatide kliinilise kasutamise optimeerimise meetmed, kuid vähestel on riiklikud prioriseerimise strateegiad, et tagada nende patsiendirühmade varustamine, kes on eriti sõltuvad ravist nende toodetega.